Stephen V. Liu, MD, discusses the expanding exploration of antibody-drug conjugates in non–small cell lung cancer.
Stephen V. Liu, MD, associate professor of medicine, Georgetown University, director of Thoracic Oncology, head of Developmental Therapeutics, Georgetown Lombardi Comprehensive Cancer Center, discusses the expanding exploration of antibody-drug conjugates (ADCs) in non–small cell lung cancer (NSCLC).
Although fam-trastuzumab deruxtecan-nxki (Enhertu) is the only ADC currently FDA approved in NSCLC, others are on the horizon, Liu says. Sacituzumab govitecan-hziy (Trodelvy) and datopotamab deruxtecan (DS-1062a), which are 2 ADCs that target Trop-2, have shown activity in patients who have received previous treatment, Liu says. These 2 ADCs are not biomarker driven, and they have shown clear signs of activity following prior therapies, Liu adds. It remains unknown if more benefit will be derived from these therapies in the frontline setting alone or in combination, Lie explains.
Tusamitamab ravtansine (SAR408701) is another ADC targeting CEACAM5 that has shown activity, Liu continues. Having a targetable biomarker can increase the chance for a beneficial response, Liu concludes.